Solid Biosciences Inc SLDB:NASDAQ

Last Price$0.84NASDAQ Closing Price as of 4:00PM ET 8/19/22

Today's Change+0.03(3.70%)
Bid (Size)$0.77 (3)
Ask (Size)$0.79 (18)
Day Low / High$0.73 - 0.88
Volume652.1 K
 

View Biotechnology IndustryPeer Comparison as of 08/19/2022

 

Solid Biosciences Inc ( NASDAQ )

Price: $0.84
Change: +0.03 (3.70%)
Volume: 652.1 K
4:00PM ET 8/19/2022
 
 

Equillium Inc ( NASDAQ )

Price: $2.77
Change: +0.07 (2.59%)
Volume: 29.9 K
4:00PM ET 8/19/2022
 
 

AquaBounty Technologies Inc ( NASDAQ )

Price: $1.32
Change: -0.03 (2.22%)
Volume: 359.7 K
4:00PM ET 8/19/2022
 
 

Atreca Inc ( NASDAQ )

Price: $2.14
Change: -0.09 (4.04%)
Volume: 112.7 K
4:00PM ET 8/19/2022
 
 

Surface Oncology Inc ( NASDAQ )

Price: $1.66
Change: -0.07 (4.05%)
Volume: 353.5 K
4:00PM ET 8/19/2022
 

Read more news Recent News

--Chardan Research Adjusts Price Target on Solid Biosciences to $6 From $7, Reiterates Buy Rating
3:52AM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Top Premarket Decliners
7:58AM ET 7/29/2022 MT Newswires

Avaya (AVYA) shares slumped 23% after the company said it now expects fiscal Q3 revenue to range from $575 million to $580 million, lower than its...

Piper Sandler Adjusts Price Target on Solid Biosciences to $2 From $5, Maintains Neutral Rating
8:01AM ET 5/19/2022 MT Newswires

Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...

--Piper Sandler Adjusts Solid Biosciences' Price Target to $5 From $6, Maintains Neutral Rating
8:52AM ET 4/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionSolid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA. View company web site for more details
Address500 Rutherford Avenue
Charlestown, Massachusetts 02129
Phone+1.617.337.4680
Number of Employees111
Recent SEC Filing08/18/2022SC 13D/A
President, Chief Executive Officer & DirectorIlan Ganot
Chief Financial Officer & TreasurerStephen J. DiPalma
Chief Scientific OfficerCarl Morris
Senior VP, Head-Clinical DevelopmentRoxana Donisa Dreghici

Company Highlights

Price Open$0.80
Previous Close$0.81
52 Week Range$0.42 - 3.42
Market Capitalization$94.9 M
Shares Outstanding113.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.77
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-588.52%
Return on Equity-44.66%

Analyst Ratings as of 08/11/2022

Buy
2
Overweight
1
Hold
1
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset